At the beginning of August, the Federal Ministry of Research, Technology and Space (BMFTR) presented its new ‘High-Tech Agenda for Germany’. The aim is to secure competitiveness, strengthen research and put innovative applications into practice by investing in future technologies. A particular focus is on health research.
In this context, the German Biobank Network (GBN) is explicitly mentioned as part of the Network of University Medicine (NUM). This highlights the importance of biobanks for an efficient research infrastructure and the translation of medical innovations into healthcare.
The agenda emphasises that medical progress will depend even more on the targeted use of comprehensive, high-quality medical data sets in the future. This includes data from clinical trials, registries, genomDE, the NAKO health study and the NUM, which has been running in its third funding phase since 1 July 2025. In addition, the agenda announces that the NUM will be institutionalised by 2026 at the latest.
Further information and links:
